Barclays raised the firm’s price target on Sotera Health to $19 from $17 and keeps an Overweight rating on the shares. The analyst says the company’s volumes remain stable in Sterigenics and Nelson and pricing drives most of growth in 2024. The firm says Sotera continues to execute while its EBITDA margins remain compressed at trough levels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SHC:
- Sotera Health Announces Secondary Offering of Common Stock
- Sotera Health Reports Fourth-Quarter and Full-Year 2023 Results; Provides 2024 Outlook
- SHC Upcoming Earnings Report: What to Expect?
- Sotera Health Announces Fourth-Quarter and Full-Year 2023 Earnings Release Date
- Tesla downgraded, UPS upgraded: Wall Street’s top analyst calls
